References in periodicals archive ?
What was not evaluated in this study was the real world use of Miacalcin Nasal Spray and Fosamax.
And Miacalcin Nasal Spray has a favorable safety profile -- no contraindications, precautions or restrictions for patients with gastrointestinal, esophageal or renal disorders.
The FDA clearance of Miacalcin Nasal Spray was based upon a new drug application (NDA) containing efficacy data from five randomized, double-blind, placebo-controlled clinical trials involving 551 postmenopausal women with osteoporosis who were studied for one to two years.
Miacalcin Nasal Spray is recommended for women who refuse or cannot tolerate estrogens or in whom estrogens should not be used.
The fact that postmenopausal osteoporosis patients and their health care providers will soon have MIACALCIN Nasal Spray available to them is very exciting positive news.